orteronel

Known as: Androgen Synthesis Inhibitor TAK-700, 6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide, 6-((7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthamide 
An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
05101520112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
PURPOSE Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined… (More)
Is this relevant?
2014
2014
PURPOSE The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer… (More)
Is this relevant?
2014
2014
PURPOSE Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment… (More)
Is this relevant?
2013
2013
Endogenous androgens play a role in the development and progression of prostate cancer (PC), thus androgen suppression may offer… (More)
  • figure 3
  • figure 4
  • figure 7
  • figure 8
  • figure 9
Is this relevant?
2012
2012
Surgical or pharmacologic methods to control gonadal androgen biosynthesis are effective approaches in the treatment of a variety… (More)
Is this relevant?
2012
2012
98 Background: The investigational agent orteronel (TAK-700) is a selective 17,20 lyase inhibitor that down regulates androgenic… (More)
Is this relevant?
2011
2011
A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17,20-lyase inhibitors. Based on the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?